The association between statin and COVID-19 adverse outcomes: national COVID-19 cohort in South Korea
- Authors
- Chow, Ronald; Lee, Jihui; Noh, Hyerim; Lee, Jongseong; Simone II, Charles B.; Shin, Hyun Joon; Choi, Young-Geun
- Issue Date
- Apr-2022
- Publisher
- AME Publishing Company
- Keywords
- Statin; coronavirus disease 2019 (COVID-19); Korean National Insurance Claims data; comparative effectiveness
- Citation
- Annals of Palliative Medicine, v.11, no.4, pp 1297 - 1307
- Pages
- 11
- Journal Title
- Annals of Palliative Medicine
- Volume
- 11
- Number
- 4
- Start Page
- 1297
- End Page
- 1307
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/151374
- DOI
- 10.21037/apm-21-3464
- ISSN
- 2224-5820
2224-5839
- Abstract
- Background: There currently exist limited and conflicting dinical data on the use of statins in coronavirus disease 2019 (COVID-19) patients. The aim of this paper was to compare hospitalized patients with COVID-19 who did and did not receive statins. Methods: We performed a population-based retrospective cohort study using South Korea's nationwide healthcare claim database. We identified consecutive patients hospitalized with COVID-19 and aged 40 years or older. Statin users were individuals with inpatient and outpatient prescription records of statins in the 240 days before cohort entry to capture patients who are chronic statin users and, therefore, receive statin prescriptions as infrequently as every 8 months. Our primary endpoint was a composite of all-cause death, intensive care unit (ICU) admission, mechanical ventilation use and cardiovascular outcomes [myocardial infarction (MI), transient cerebral ischemic attacks (TIA) or stroke]. We compared the risk of outcomes between statin users and non-users using logistic regression models after inverse probability of treatment weighting (IPTW) adjustment. Results: Of 234,427 subjects in the database, 4,349 patients were hospitalized with COVID-19 and aged 40+ years. In total, 1,115 patients were statin users (mean age =65.9 years; 60% female), and 3,234 were nonusers (mean age =58.3 years; 64% female). Pre-hospitalization statin use was not significantly associated with increased risk of the primary endpoint [IPTW odds ratio (OR) 0.82; 95% confidence interval (CI): 0.60-1.11]. Subgroup analysis showed a protective role of antecedent statin use for individuals with hypertension (IPTW OR 0.40; 95% CI: 0.23-0.69, P for interaction: 0.0087). Conclusions: Pre-hospitalization statin use is not detrimental and may be beneficial amongst hypertensive COVID-19 patients. Further investigation into statin is needed for more conclusive effects of statins for treatment of COVID-19.
- Files in This Item
-
- Appears in
Collections - 이과대학 > 통계학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.